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Abstract
Background: Over the last few years a decreasing trend in smoking has occurred not only in the general
population but also during pregnancy. Several countries have implemented laws requiring all enclosed workplace
and public places to be free of second hand smoke (SHS). In Spain, legislation to reduce SHS was implemented in
2005. The present study examines the possible effect of this legislation on prenatal SHS exposure.
Methods: Mothers and newborns were recruited from 3 independent studies performed in Hospital del Mar
(Barcelona) and approved by the local Ethics Committee: 415 participated in a study in 1996-1998, 283 in 2002-
2004 and 207 in 2008. A standard questionnaire, including neonatal and sociodemographic variables,tobacco use
and exposure during pregnancy, was completed at delivery for all the participants in the three study groups. Fetal
exposure to tobacco was studied by measuring cotinine in cord blood by radioimmunoassay (RIA).
Results: 32.8% of the pregnant women reported to smoke during pregnancy in 1996-1998, 25.9% in 2002-2004
and 34.1% in 2008. In the most recent group, the percentage of no prenatal SHS exposure (cord blood cotinine
0.2-1 ng/mL) showed an increase compared to the previous groups while the percentages of both: low (1.1-14 ng/
mL) and very high (> 100 ng/mL) prenatal SHS exposure showed a decrease.
Discussion: The results of the three study periods (1996-2008) demonstrated a significant increase in the
percentage of newborns free from SHS exposure and a decrease in the percentage of newborns exposed to SHS
during pregnancy, especially at the very high levels of exposure. A significant maternal smoking habit was noted in
this geographical area with particular emphasis on immigrant pregnant smoking women.
Conclusions: Our study indicates that there is a significant maternal smoking habit in this geographical area. Our
recommendation is that campaigns against smoking should be directed more specifically towards pregnant
women with particular emphasis on non-native pregnant smokers due to the highest prevalence of tobacco
consumption in the immigrant women.
Background
Exposure to second hand smoke (SHS), active or pas-
sive, is considered the single most important cause of
avoidable morbidity and early mortality in many indus-
trialized countries [1]. Over the last years, Spain pre-
sented a decreasing trend in smoking not only in the
general population but also during pregnancy [2-5];
however it is still an important risk factor for infant
health. Most recent population data from Barcelona
documented that 28% of pregnant women smoke at the
beginning of pregnancy, and although 42% of them quit
during the gestational period, 16% smoke throughout
pregnancy [5] therefore the gestational and fetal effects
of cigarette smoke are of great importance for public
health [6]. The effects of tobacco smoke exposure on
the health of pregnant women are associated with an
increased risk of spontaneous abortion, low birth weight,
prematurity, perinatal death and sudden infant death
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syndrome [7-9]. while the risk of cognitive problems and
neurodevelopment growth [10], childhood cancer [11]
and respiratory and allergic symptomatology in the first
years of life [12] can be increased as well.
There is scientific evidence that smoke-free environ-
ment is the only strategy protecting the population from
the negative effects of SHS [13]. For this reason, several
countries have implemented legislations requiring all
enclosed workplace and public places to be free of SHS
[14]. Ireland was the first country with comprehensive
smoke-free legislation implemented in 2004. Since then,
countries like Norway, New Zealand, Italy, Uruguay,
England and many provinces or states in Canada, the
USA or Australia [15,16] followed. Recently, by measur-
ing air nicotine concentrations, a study had shown that
exposure to second hand smoke has decreased greatly in
indoor public places and workplaces in Uruguay after
the implementation of a comprehensive national smoke-
free legislation [17].
Spain introduced the legislation to reduce SHS in
2005. The Law 28/2005 includes a health recommenda-
tions against smoking and recommendations forregula-
tion of tobacco smoking in public places with wide
exemptions in bars, restaurants and night clubs [18,19].
Furthermore, the implementation of smoke-free legisla-
tion generated a continuous discussion topic in the
media [20]. After the implementation of the Spanish
smoke-free legislation [3,4,21-23], programs to help
smoking pregnant women to quit were implemented
(program “Embaràs fum”) in Catalonia. These programs
included specific training and free nicotine replacement
treatment for pregnant smoking women throughout
pregnancy [24].
Prenatal tobacco exposure has been usually assessed
using self-reported maternal questionnaire [25-28]. Diffi-
culties in differentiating passive tobacco exposure from
active smoking (such as reluctance to admit active
smoking or being unconscious of passive exposure) have
prompted the use of specific biomarkers to prevent bias
in self-reporting questionnaires [29,30]. Nicotine and its
main metabolite (cotinine) have been used as biomar-
kers for SHS in conventional (blood and urine) [31,32]
and non-conventional matrices (saliva, meconium and
hair) [33,34]. Cotinine presents a longer biological half-
life than nicotine and it is considered the best biochem-
ical marker to differentiate between active and passive
tobacco exposure [33,35-37]. Moreover, the levels of
cotinine have been found to be directly related to daily
cigarette consumption [35]. Cotinine cord blood is the
most sensitive and least invasive measure of prenatal
SHS in newborns [36-42].
The present study examines the possible effects of the
actions taken to prevent prenatal SHS exposure. The
relationship between the implementation of the law
against smoking and a decrease in maternal tobacco use
and exposure during pregnancy has been studied by
measuring cotinine in cord blood as a reliable biomarker
of active and/or passive maternal exposure to SHS. In
addition, the relationship between the newborn’s coti-
nine level in cord blood and the parents’ smoking pat-
tern declared by questionnaire has been also evaluated.
Methods
Design and subjects
The study was carried out on non selected (general
population) mothers and newborns from 3 independent
studies conducted at different times in the same setting:
Hospital del Mar in Barcelona (Catalonia, Spain
Study 1
415 mothers and their infants were recruited during the
period 1996-98, from the Asthma Multicenter Infant
Cohort Study (AMICS). The AMICS study was designed
to investigate the effects of several pre and postnatal
environmental exposures on the inception of atopy and
asthma [12,29,41,43].
Study 2
283 mothers and their infants were recruited from 2002
until 2004, before the general implementation of smoke-
free workplace policy in Spain in 2005, from the
MECONIUM-1 study. The MECONIUM-1 study aimed
to estimate the prevalence of using drugs of abuse by
pregnant women and the subsequent foetal exposure to
illicit drugs by testing the meconium of the newborn
[44].
Study 3
207 mothers and their infants were recruited during
2008, after the implementation of smoke-free workplace
policy in Spain, from MECONIUM-2 study. The
MECONIUM-2 study aimed to estimate the prevalence
of alcohol use by pregnant women and the subsequent
foetal exposure to alcohol using meconium testing [45].
Informed consent was obtained from parents and all
three studies were previously approved by the local
Ethics Committee (Comitè d’Ètica i Investigació Clínica,
Institut Municipal d’Assistència Sanitària; 2006/2831/I-
extension).
Questionnaire information
The same standard questionnaire previously reported in
the literature [12,29,33,37,41] was completed at delivery
for all the participants, regardless of the group they
belonged to. The questionnaire was always administered
by the study interviewer immediately after postpartum
and included sociodemographic characteristics (parents’
age, parents’ birth country, social class defined by par-
ents’ occupation using the UK Registrar General’s 1990
classification which categorizes people with similar levels
of occupational skills). In addition, mothers were asked
Puig et al. BMC Pregnancy and Childbirth 2012, 12:26
http://www.biomedcentral.com/1471-2393/12/26
Page 2 of 8
about their smoking habit and passive exposure to
tobacco smoke during pregnancy. If they were smokers,
the average number of cigarettes smoked during preg-
nancy was recorded and the nicotine daily intake (NDI),
obtained from the average number of cigarettes smoked
per day multiplied by nicotine content (in milligrams) of
each cigarette, was calculated. Regarding exposure to
SHS, mothers were asked if they were regularly exposed
to SHS at home and by whom (nobody smoked, the
father or the mother was the only smoker or both
smoked). The gender of the newborn was also recorded.
Cotinine in cord blood
Umbilical cord blood was obtained at the time of deliv-
ery and immediately centrifuged. Serum was collected
and stored at -80°C until analysis. Cotinine was analysed
by RIA. The detectable range of measurement from the
standard curve was 0.2-20 ng/mL cotinine, with an
interassay coefficient of variation of 6-10%. A cut-off
value of 14 ng/mL (previously proposed by different
authors) was used for cord serum cotinine to discern
between newborns of non-smoking mothers from smok-
ing mothers [30]. Newborns exposed to SHS were cate-
gorised according to cord blood cotinine level as non
exposed (cord serum cotinine < 1 ng/mL), low exposure
(cord serum cotinine from 1 to 14 ng/mL), medium
exposure (cord serum cotinine from 14 to 50 ng/mL),
high exposure (cord serum cotinine > 50 ng/mL) and
very high exposure (cord serum cotinine > 100 ng/mL)
[30,37].
Statistical methods
We compared sociodemographic data of different study
groups using the Chi-square test or Fisher’s exact test
for categorical variables and Student’s t-test for continu-
ous variables. Furthermore, to compare parental smok-
ing habits among each period of the study a logistic
regression analysis with odds ratio (OR) was conducted.
To assess the relationship between parental smoking
habit and the mean cord blood cotinine levels, a univari-
ate statistical analysis was used with cotinine levels as
continuous variable and parental smoking habit as ran-
dom factor. The categories of prenatal exposure were
assessed by logistic multinomial regression. The inde-
pendent variables were adjusted for socioeconomic sta-
tus, mother and father’s nationalities, mother’s age and
newborn’s sex. Differences associated with p values
lower than 0.05 were considered statistically significant.
The SPSS program (version 16.0, SPSS Inc, Chicago, IL,
USA) was used for the analysis of data.
Results
Table 1 shows the socioeconomics characteristics of the
study groups. The differences between the 3 periods
studied reflect the sociodemographic changes in the
population attending at the Hospital del Mar. Recently,
the percentage of foreign immigrants has increased sig-
nificantly (practically doubled); the percentage of profes-
sionals has also grown as a result of a higher number of
middle class people being attracted by the sea-side life
in Barcelona.
Parents’ smoking habit
According to the self-reported questionnaires, 32.8% of
the pregnant women reported daily smoking during
pregnancy in 1996-98, 25.9% in 2002-04 and 34.1% in
2008; the statistics don’t show significant differences in
the number of mothers who smoked throughout preg-
nancy over the 12 years of the study. There were no sig-
nificant differences between the groups regarding the
self-reported tobacco use if maternal smoking expressed
as NDI among the 3 groups of study is compared: mean
= 5.60 (range: 0.80-28.00) in 1996-98, mean = 7.50
(range: 0.70-32.00) in 2002-04 and mean = 10.50 (range:
1.20-32.00) in 2008.
Assessing how smoking habit in families has varied
with respect to mother’s country of origin, a reduction
in native homes where only the father was smoking:
29.6% in 1996-1998 and 13.7% in 2002-2004 (OR: 0.46;
CI 95%: 0.23-0.95) was observed; however, this trend
was not maintained in 2008 (25.7%). In homes where








Mother’s age, mean (SD) 29.1 (5.4) 29.0 (6.1) 30.6 (6.2)
Father’s age, mean (SD) 32.0 (6.0) NA 33.3 (7.0)
Mother’s nationality (Spain), % 74.5 51.3** 46.6
Father’s nationality (Spain), % 74.8 51.3** 44.6
Mother’s working (yes), % 51.8 52.8 61.9
Father’s working (yes), % 91.8 91.4 95.4
Mother’s profession, % 6.9 10.8* 14.6†
Professional 17.5 12.4 12.5
Managerial and technical 37.6 35.8 41.6
Skilled (non-manual) 21.7 24.5 18.8
Skilled (manual) 16.4 16.5 12.5
Unskilled
Father’s profession, % 6.2 8.9 16.7†
Professional 10.7 10.9 6.9
Managerial and technical 22.7 19.4 12.5
Skilled (non-manual) 57.8 56.6 58.3
Skilled (manual) 2.6 4.2 5.6
Unskilled
NA: not available
* p-value in relation to 1996-98; p-value < 0.05
** p-value in relation to 1996-98; p-value < 0.001
† p-value in relation to 2002-04; p-value < 0.05
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only the mother was smoking, there was an increase
from 1996-1998 (11.5%) to 2002-2004 (25.5%) (OR: 2.31;
CI 95%: 1.18-4.52) and although this trend was broken
in 2008 (14.3%), it was without statistical significance.
There was no significant change in homes with both
parents smoking. In immigrant homes, there were no
differences in the three study periods when only the
father (34.1%, 22.4% and 23.1%) or only the mother
(4.5%, 7.1% and 10.3%) were smoking; the number of
homes where both parents were smoking was 3.4% in
1996-1998, 5.9% in 2002-2004, and increased to 23.1%
in 2008 (OR: 5.82; CI 95%: 1.72-19.75).
Cotinine as biomarker of fetal SHS
The mean cord blood cotinine levels in the newborns
from all the study groups were: 3.21 (range: 0.20-910.00)
in 1996-98, 0.80 (range: 0.20-250.00) in 2002-04 and
0.44 (range: 0.20-128.00) in 2008.
Table 2 shows the stratification of prenatal SHS expo-
sure based on cord blood cotinine in the five categories
defined previously. The stratification criteria were the
same as in a previous publication [37]. The results show
an increase in the percentage of no SHS exposure in the
most recent group compared to the previous groups
while the percentages of both prenatal SHS exposure
categories: low (1.1-14 ng/mL) and very high (> 100 ng/
mL) show a decrease.
It is important to highlight that the higher decrease in
the prevalence of SHS exposure occurred in the period
from 1996-98 to 2002-04, but the downward trend was
maintained from to 2002-04 to 2008.
Validity of the biomarker
Table 3 shows that in the first two groups of study there
is a good correlation between the number of self-
reported smoking parents and cord blood cotinine
levels. Clearly, cord blood cotinine level is slightly higher
when the father is the only smoker compared when
neither parent is a smoker; but when the mother
smokes, the increase is much higher. For 2008 the trend
is the same, however the differences are smaller without
reaching statistical significance.
To distinguish between newborns from smoking and
non-smoking mothers, the cut-off of 14 ng/mL for cord
serum cotinine was used. Table 4 shows that cord blood
cotinine levels higher than 14 ng/mL correspond to
smoking mothers (75.5 - 90.9%), with the exception of
2008 where cord blood cotinine levels are lower for the
entire group due to less SHS.
Discussion
The results show a decreasing trend of exposure to SHS
and an increase of prenatal non-exposure to SHS. This
improvement was significant before the implementation
of Spanish free-smoke legislation in 2005 and maintains
the tendency after it. Globally, there was no change in
the percentage of women smoking during pregnancy
along the years, but there was an increase in the number
of non-Spanish women who smoked during pregnancy.
Prenatal exposure
Our results demonstrate that in recent years the expo-
sure to SHS has decreased as evidenced by a higher per-
centage of samples with cord blood cotinine < 1 ng/mL;
at the same time prenatal exposure to low levels of SHS
decreased in recent years (cord blood cotinine in the
interval of 1.1 to 14 ng/mL). This reduction in SHS
exposure has been observed in England (by question-
naire and cotinine in saliva) [46] and Italy (by question-
naire and cotinine in cord blood) [16,47], The present
study adds the objective advantage of serial biomarker
determinations.
Moreover, the very high prenatal exposure to SHS
(cord blood cotinine > 100 ng/mL) has decreased in all
the three groups studied. It is important to point out a
more marked decrease in prenatal SHS in 2002-04
immediately before the implementation of Spanish
smoke-free legislation.
The growing implication of health care services in
smoking cessation, the marked presence of negative
Table 2 Prenatal SHS exposure by measuring cotinine in cord blood
1996 - 98 2002 - 04 2008
N = 415 N = 283 N = 207
Level of prenatal SHS (cotinine ng/mL) % % OR (CI 95%) OR Adjust (CI 95%) % OR (CI 95%) OR Adjust (CI 95%)
Non exposure < 1 10.8 56.9 1.18 (1.11-1.26) ** 1.14 (1.06-1.22) ** 73.4 1.20 (0.97-1.48) 1.22 (0.96-1.55)
Low exposure 1-14 54.9 19.8 0.88 (0.82-0.93) ** 0.86 (0.80-0.92) ** 12.1 0.93 (0.73-1.20) 0.99 (0.75-1.31)
Medium exposure 14-50 9.4 11.0 1 1 8.2 1 1
High exposure 50-100 7.5 8.8 1.00 (0.93-1.08) 1.01 (0.93-1.10) 3.9 0.84 (0.60-1.16) 0.83 (0.56-1.23)
Very high exposure > 100 17.3 3.5 0.82 (0.75-0.90) ** 0.83 (0.76-0.91) ** 2.4 0.97 (0.64-1.46) 0.99 (0.64-1.55)
Adjust: adjusted by gender of newborn, age and mother’s nationality
* p-value in relation to 1996-98; p-value < 0.05
** p-value in relation to 1996-98; p-value < 0.001
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messages regarding tobacco in the media and the public
dialog prompted by the imminent implementation of
smoke-free legislation may have had a cumulative effect
on the decreasing trend of smoking prevalence. Follow-
ing that period, the effect has been maintained due to
the implementation of smoke-free legislation and due to
the mass media pressure.
Furthermore, our study reasserts the importance of
maternal smoking habit during pregnancy. Cotinine
levels in newborns are slightly higher when the father
smokes compared with the families where neither parent
is a smoker. The cotinine levels increase a significantly
when the mother is a smoker. In this stage of life, the
importance of active maternal smoking is related to the
direct passage of cotinine to the foetus across the pla-
centa. This is different from maternal passive SHS when
the father smokes; in this case, cotinine arrives to foetus
through cord blood, after the mother inhaled the smoke.
Maternal smoking habit
Cord blood accounts for foetal tobacco exposure during
the previous days or hours before collection and not for
chronic exposure during the entire gestation. Neverthe-
less, cord serum cotinine appeared to be the most ade-
quate biomarker of foetal exposure to smoking at the
end of pregnancy, distinguishing not only active smok-
ing from passive smoking, but also exposure to ETS
from nonexposure [29,33,37,43]. Studying the percen-
tage of women who reported daily smoking during
pregnancy, it becomes clear that the data from the self-
reported questionnaire (32.8, 25.9 and 34.1%) does not
show a significant variation in the patient population
between the different periods of study while the percen-
tage of newborns with cord blood cotinine > 14 ng/mL
is decreasing progressively (34.2, 23.3 y 14.5%, respec-
tively). The discrepancy between percentages reported
by self-reported questionnaire and cord blood cotinine
level that identify newborns from smoking mothers
could be explained if one takes into consideration that
the questionnaire inquires about the entire gestational
period while the analytical value of cord blood cotinine
refers only to the end of the pregnancy. We believe
these data indicate that due to implementation of
smoke-free legislation, maternal exposure to SHS in the
hours just before delivery has decreased significantly.
The obtained results suggest that cord blood cotinine
can be a useful biomarker in population studies moni-
toring the prevalence of SHS exposure and in preventing
a bias related to self-report of active smoking or passive
exposure or reluctancy to admit it. Maternal hair would
be an adequate reference matrix [43] but it has metho-
dological problems of standardization and accessibility
as proven in clinical environment and public health
studies.
The strong points of this study are that it is the first
study that includes data collected before and after the
implementation of Spanish smoke-free law and the
prenatal exposure to SHS has been studied objectively
Table 3 Parental smoking habit declared by self-report and probability distribution (mean, median and geometric
mean) of cord blood cotinine level
Parental smoking habit Cord blood cotinine levels (ng/mL)
1996 98 2002 04 2008
N = 373 N = 245 N = 181
GM Median Mean (SD) p-value GM Median Mean (SD) p-value GM Median Mean (SD) p-value
Nobody 1.8 1.6 8.4 (57.4) Ref. 0.4 0.4 0.6 (0.8) Ref. 0.6 0.37 3.5 (7.9) Ref.
Only father 3.1 2.4 16.2 (55.5) 0.6 0.5 2.3 (6.4) 0.9 0.31 7.0 (17.3)
Only mother 62.5 74.6 132.4 (183.1) ** 55.6 75.5 74.9 (50.0) ** 0.7 0.36 9.6 (27.7)
Both 78.1 97.2 162.0 (170.0) ** 20.8 28.7 39.8 (37.6) ** 0.9 0.29 14.5 (36.1)
GM: geometric mean; Ref.: reference
** p-value in relation to “Nobody smoke"; p-value < 0.001
Table 4 Parental smoking habit and cotinine levels in cord blood higher 14 ng/mL
Parental smoking habit Cord blood cotinine levels > 14ng/mL
1996 98 2002 04 2008
N = 373 N = 245 N = 181
n % n % n %
Nobody 5 3.9 (5/128) 0 0.0 (0/109) 6 7.7 (6/78)
Only father 13 11.8 (13/110) 3 6.9 (3/43) 6 15.0 (6/40)
Only mother 43 86.0 (43/50) 40 90.9 (40/44) 4 14.8 (4/27)
Both 77 90.6 (77/85) 37 75.5 (37/49) 6 16.7 (6/36)
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by a biomarker measured in a non conventional
matrix; it is non invasive for the newborn and prevents
the bias inherent to maternal self-reports. Data com-
parison for different biomarkers in general population
during the same period is not available at the moment
but it could prove useful in the future. It should be
interesting to collect new data after a longer period in
order to confirm the stability and the trend in the data
obtained.
There may be other factors that have an impact as
tobacco control measures: negative messages in mass
media campaigns and the public awareness derived from
them, the increase in the price of tobacco, and specific
public health programs to help smoking pregnant
women quit. Nevertheless, our data suggest that the
implementation of smoke-free legislation is on the right
track in reaching one of its objectives: to “guarantee the
non-smokers’ rights to breath smoke- free air” as
demonstrated by the lower cord blood cotinine level in
newborns. However, we can not affirm that it had gen-
erated changes to facilitate the “smoking cessation by
active smokers”. The Cochrane review does not demon-
strate a conclusive relationship between media cam-
paigns against smoking in adults and the decrease of
tobacco use; the
report about the impact of Spanish Law 28/2005 is
pointing in the same direction [48,49]. For this reason,
it is necessary to consider other preventivemeasures, as
specific actions focused on pregnant women according
to the local demographic changes.
Conclusions
The three study periods (1996-2008) demonstrated a
significant increase in the prevalence of newborns free
of SHS exposure and a decrease in the prevalence of
newborns exposed to SHS during pregnancy, especially
at the very high levels of exposure. The change could be
explained as a combination of several factors: negative
messages in communication media and the public
awareness derived from them; the implementation in
2005 of Spanish smoke-free legislation; and the increase
in the tobacco price for the fiscal modification.
It is necessary to maintain and intensify the campaigns
against prenatal SHS using communication media, more
extensive and severe implementation of smoke-free leg-
islation and educational actions in favour of decreasing
the smoking habit among pregnant women. All these
interventions will make it possible to improve the pre-
sent results in the future [50].
Our study indicates that there is a significant maternal
smoking habit in this geographical area. Our recommen-
dation is that campaigns against smoking should be
directed more specifically towards pregnant women with
particular emphasis on non-native pregnant smokers
due to the highest prevalence of tobacco consumption
in the immigrant women.
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